Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Daiichi Sankyo

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.

Daiichi Sankyo

AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate

AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate

Datopotamab deruxtecan shows early promise in heavily pre-treated patient group. AstraZeneca (AZ) and Daiichi Sankyo have revealed new data for their second next-generation antibody drug conjugate (ADC), datopotamab deruxtecan ... Both companies will

AZ strengthens Daiichi Sankyo partnership with new ADC deal

AZ strengthens Daiichi Sankyo partnership with new ADC deal Deal for experimental antibody drug conjugate could reach $6bn. AstraZeneca (AZ) has invested up to $6bn in a new partnership with Japanese pharma company Daiichi Sankyo (Daiichi) for the development of ... We are delighted to enter this new

Merck expands partnership with Zymeworks for multispecific antibodies

Merck expands partnership with Zymeworks for multispecific antibodies Aside from Merck, Zymeworks has inked deals with a number of major pharma companies, including Eli Lilly, Celgene, GlaxoSmithKline and Daiichi Sankyo.

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug Antibody drug conjugate gained approval in US in December. The European Medicines Agency (EMA) has accelerated the assessment of Daiichi Sankyo and AstraZeneca’s HER2-positive breast cancer candidate, fast-tracking ... Trastuzumab deruxtecan is central

Cortellis Drugs to Watch in 2020 report

Cortellis Drugs to Watch in 2020 report 10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....